Rare disease is a major – and growing – area of clinical research and drug development. Of the FDA’s 46 novel drug approvals ...
WPP’s restructuring under Cindy Rose signals the end of the legacy agency brand era, as AI, consolidation, and ...
For 2026, Rightmove reiterated guidance for revenue growth of 8% to 10%, against Jefferies’ consensus estimate of 8.7%, and ...
Addressing reliable, accurate, and fast-acting voltage supervision that enables the reliable deployment of next-generation DC ...
Recent corporate filings referenced share activity and ongoing market participation. Cloud based enterprise software sits ...
Streaming momentum and disciplined cost control offset a softer advertising market. The post Nine shares jump 4% as Stan and ...
The federal Liberals have accepted amendments to the most controversial section of the Carney government's budget bill, ...
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has ...
The sharpest declines were recorded in its broadcast arm, weighed down by the Nine television network and 9Now. But Stan was the star performer, growing revenues by 15%, by rising the price of ...
The reason I’ve chosen to discuss them is, based on returns over the past year, they’re the two best performing trusts screened this month according to our twin value and momentum criteria. BlackRock ...
Moderna, Inc. (NASDAQ: MRNA) shares are swinging in volatile early trading on Friday, February 27, 2026, as investors digest ...
There are defining moments in the life of a nation—moments when existing conditions demand deliberate choice. For The Gambia, such a moment centers on Banjul.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results